Hester Biosciences Ltd (HESTERBIO) Q1FY27 Concall Summary - Jun-2026 Qtr
Performance Overview
- The company demonstrated strong standalone performance in Q1 FY27, with revenue growing by 14% and profit after tax (PAT) increasing by a significant 88% year-over-year, indicating robust operational execution.
- Gross margins saw a substantial improvement, rising from 69% to 78%, primarily driven by a more favorable product mix and sustained efforts in enhancing operational efficiency.
- The Poultry Health Care division was the standout performer, delivering exceptional 48% year-over-year growth, fueled by increased institutional business and deeper market penetration.
- The Animal Health Care division's performance was subdued due to the timing of government-led immunization programs, a factor the management views as a temporary delay rather than a fundamental demand issue.
- On a consolidated basis, revenue growth was a more modest 8%, impacted by lower revenues from the Nepal and Africa operations, though the company remains committed to its long-term strategy in these international markets.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.